Related Experiment Video
Updated: Jun 22, 2025
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
CTLA-4 silencing could promote anti-tumor effects in hepatocellular
Amirhossein Mardi1,2,3, Mahsan Alizadeh4, Amir Shahabaddin Abdolalizadeh4
1Student Research Committee, Tabriz University of Medical Science, Tabriz, Iran.
Abstract:
Preclinical and clinical research showed that immune checkpoint blockade provides beneficial effects for many patients with liver cancer. This study aimed to assess the effect of CTLA-4-specific siRNA on the proliferation, cell cycle, migration, and apoptosis of HePG2 cells. Transfection of siRNA was performed by electroporation. The viability of cells was determined through MTT assay. Flow cytometry was performed to investigate the cell cycle and apoptosis rate, and the wound-healing assay was used to determine HepG2 cells migration. The expression levels of CTLA-4, c-Myc, Ki-67, BCL-2, BAX, caspase-9 (CAS9), and MMP-2,9,13 were measured by qRT-PCR. Transfection of specific CTLA-4-siRNA significantly inhibited the expression of the CTLA-4 gene. Also, our results revealed that CTLA-4 silencing diminished the proliferation and migration as well as induced the apoptosis of HePG2 cells. CTLA-4-siRNA transfection induced the cell cycle arrest in G2 phase. Moreover, CTLA-4-siRNA transfection reduced the expression levels of c-Myc, Ki-67, BCL-2, MMP-2,9,13, and elevated the expression levels of BAX and caspase-9. Our results suggest that silencing CTLA-4 through specific siRNA may be a promising strategy for future therapeutic interventions for treating liver cancer.
Insights
Silencing CTLA-4 with siRNA inhibits liver cancer cell growth, migration, and induces apoptosis. This suggests CTLA-4 siRNA as a potential therapy for liver cancer.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Immune checkpoint blockade shows promise in liver cancer treatment.
- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a key immune checkpoint target.
Purpose of the Study:
- To investigate the therapeutic potential of CTLA-4-specific siRNA in liver cancer.
- To assess the impact of CTLA-4 silencing on HepG2 cell proliferation, cell cycle, migration, and apoptosis.
Main Methods:
- HepG2 cells were transfected with CTLA-4-specific siRNA via electroporation.
- Cell viability, proliferation, cell cycle, apoptosis, and migration were analyzed using MTT assay, flow cytometry, and wound-healing assays.
- Gene expression levels of CTLA-4, c-Myc, Ki-67, BCL-2, BAX, caspase-9, and MMPs were quantified using qRT-PCR.
Main Results:
- CTLA-4-specific siRNA significantly reduced CTLA-4 gene expression in HepG2 cells.
- Silencing CTLA-4 inhibited cell proliferation and migration, and induced apoptosis.
- CTLA-4 siRNA transfection led to G2 phase cell cycle arrest and altered expression of key regulatory genes (c-Myc, Ki-67, BCL-2, BAX, caspase-9, MMPs).
Conclusions:
- CTLA-4-specific siRNA demonstrates significant anti-cancer effects on liver cancer cells.
- Targeting CTLA-4 with siRNA represents a promising therapeutic strategy for liver cancer treatment.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
11:44Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy